Celtic Pharma Stephen Evans-Freke Stephen Evans-Freke and John Mayo read more.

About Celtic Pharmaceutical Holdings LPCeltic Pharmaceutical Holdings LP is a global private equity firm is on the focused Fact sheets on the health effects of drugs and further information on NIDA research on the NIDA website at biotechnology and pharmaceutical industries. Celtic Pharma Stephen Evans-Freke Stephen Evans-Freke and John Mayo, CBE and is in Bermuda, with offices in New York and London read more . Celtic Pharma acquires and invests in late stage pharmaceutical programs and drives these programs through the final stages of regulatory approval. Celtic Pharma ‘s aim, the gap between the established pharmaceutical companies’ new product pipeline crisis and the biotech sector to bridge capital drought. For more information.

Celtic Pharma Announces Preliminary Results of Phase 2 clinical studies with TA-CD, Cocaine Addiction VaccinePreliminary results from two Phase 2 studies of TA-CD, a novel immunotherapy vaccine for the treatment of cocaine addiction, the sponsored by the National Institute on Drug Abuse , were on 16 June 2006 presented and evaluated at a meeting in Scottsdale, NIDA officials, a panel of drug addiction experts from leading U.S. Research institutions and the Celtic Pharma team.

In phase two TRA – PCI report TRA typically for each of the at each of the doses tested. The discontinuation rate due to adverse events were 6 % TRA and 5 % of with placebo.

The stage III of clinical development program includes two large clinical studies, to risk reduction through TRA – BEAUTIFUL 530348 evaluating plus CT treatment with a platelet aggregation inhibitors in comparison to placebo plus CT therapeutic is provided antiplatelet at both groups – both acute coronary syndrome patients and. For secondary prevention of patients that have a prior MI or stroke as well some patients with peripheral occlusive arterial illness The attempts of be carried out in approximately 30 countries of more than 800 locations on each trial. New Orleans, of our novel selective thrombocyte aggregation inhibitors TRA entered phase III a major milestone to connect of researchers at Schering-Plough Research Institute, which is discovered the potential to treat a disease with significant unmet medical need, ‘commented Thomas P. Koestler, executive vice president and president of, Ernst Schering-Plough Research Institute.